REVUFORJ Gets FDA Patent Timer: Generic Delays on Deck
Published Date: 2/26/2026
Notice
Summary
The FDA has set the official review period for the drug REVUFORJ, which helps the company extend its patent and protect their invention longer. This affects the drug maker and anyone tracking patent timelines, with deadlines to challenge or comment by April 27 and August 25, 2026. It’s a key step in making sure the patent extension process is fair and on schedule, potentially impacting when generic versions can enter the market.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
FDA Sets REVUFORJ Review Length
The FDA determined REVUFORJ had a regulatory review period of 1,969 days total: 1,674 days in the testing phase and 295 days in the approval phase. Those totals are based on an investigational exemption effective June 28, 2019, an NDA submission on January 26, 2024, and approval on November 15, 2024.
Applicant Requests 525-Day Patent Extension
The patent applicant (Vitae Pharmaceuticals, LLC) has applied to the USPTO seeking 525 days of patent term extension for U.S. Patent No. 10,683,302 covering REVUFORJ. FDA's determination of the regulatory review period establishes the maximum potential length of any extension the USPTO may consider.
Determination May Affect Generic Entry Timing
FDA’s determination establishes the maximum potential patent extension period that the USPTO may use when calculating any patent term restoration, and the USPTO will apply statutory limitations in its final calculation. That process can affect when generic versions of REVUFORJ are legally able to enter the market.
Deadlines to Challenge or Petition
Anyone who believes the published dates are incorrect may ask for a redetermination by April 27, 2026, and any interested person may petition FDA about the applicant's diligence during the regulatory review period by August 25, 2026. Petitions must meet the requirements in 21 CFR 60.30 and be timely and properly filed.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03843 — Agency Information Collection Activities: Proposed Request
The Social Security Administration wants your thoughts on some forms they use to pick people who manage benefits for others. They’re updating these forms and asking for feedback by April 27, 2026, to make sure the process is clear and easy. This affects individuals and organizations applying to be payees, with no new costs but a chance to reduce paperwork hassle.
Next: 2026-03848 — Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
The FDA has set the official review period for ORLYNVAH, a human drug, which helps decide how long its patent can be extended. This affects the drug’s maker by potentially giving them more time to protect their invention and earn money. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until April 27 or August 25, 2026, to speak up.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in